SPEEDX
12.8.2021 00:02:10 CEST | Business Wire | Press release
SpeeDx Pty. Ltd. announced today their Plex PCR® SARS-CoV-2* test received clearance from the Australian Therapeutic Goods Administration (TGA). Designed from a database of over 1,000,000 sequences, the two gene, single-well test detects all current circulating variants§ of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19. The test is ideally suited to support rapid response to outbreaks, offering scalable 96- or 384-well capacity, automated software reporting, and liquid handling robotics in the form of the SpeeDx Plex Prep™ . The combination of Plex Prep™ robotics and automated software analysis can support a scalable workflow for throughputs of 480 to 1,920 patient samples in an 8-hour shift.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210811005891/en/
“We have been supporting labs around the world with their COVID-19 testing needs, and we are very happy to extend that service to our local healthcare providers,” said Colin Denver, SpeeDx CEO. “Throughout the pandemic, labs across Australia faced supply challenges from many of the global diagnostic providers, and we are passionate about improving sovereign capacity in this space.”
The addition of Plex PCR® SARS-CoV-2 expands SpeeDx’s respiratory testing menu that includes Plex PCR® RespiVirus* - a two-well multiplex assay for the detection of 14 targets from 11 viral respiratory-illness causing pathogens including Influenza A, Influenza B, and Respiratory Syncytial Viruses (A & B). A respiratory bacteria is also planned to further build SpeeDx’s respiratory infectious disease test portfolio.
SpeeDx recently leveraged their unique mutation detection approach to launch the Plex Prime® SARS-CoV-2 Genotyping portfolio, a range of research reagents supporting laboratory and epidemiological investigations of SARS-CoV-2 newly circulating variants. Investigations connected to Variants of Concern (VOC) show evidence of increased transmissibility, reduced vaccine efficacy, and other attributes that may require specific public health actions.1 There are also emerging Variants of Interest (VOI) appearing in increased proportions or in outbreak clusters. SpeeDx proprietary Plex Prime® and Plex Zyme® technology allows for mutation-specific amplification and detection – a highly sensitive approach that can also simultaneously analyse multiple mutations. Current practices involve multiple-well tests or sequencing analysis, all of which extend the turn-around-time to result. SpeeDx advanced multiplex technology reduces the number of wells required, resulting in a simplified process with increased throughput to accelerate turnaround of variant investigations.
The addition of Plex PCR® SARS-CoV-2 and associated products broadens SpeeDx’s available testing menu from the current suite of tests for sexually transmitted infections and antimicrobial resistance markers that include Resistance Plus ® MG† and Resistance Plus ® GC† – supporting Resistance Guided Therapy for Mycoplasma genitalium and gonorrhoea respectively – and Plex PCR® VHS† , a multiplex lesion diagnostic test.
*not available in the U.S.
§ based on in silico investigation as of August 2021
About SpeeDx
Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. SpeeDx has a portfolio of CE-IVD kits for detection of infectious disease pathogens, sexually transmitted infection (STI), and antimicrobial resistance markers. SpeeDx ResistancePlus tests enable Resistance Guided Therapy, improving patient outcomes by empowering practitioners to make informed clinical decisions.
For more information about SpeeDx please see: http://plexpcr.com
References
- Centers for Disease Control and Prevention, SARS-CoV-2 Variant Classifications and Definitions. found at: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html last updated May 17, 2021.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210811005891/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Eighteen48 Partners Announces First Close of Eighteen48 Private Equity Fund I at €175 million14.5.2026 13:56:00 CEST | Press release
Eighteen48 Partners today announced the first close of Eighteen48 Private Equity Fund I (the “Fund”) at €175 million. The Fund, which is targeting €350 million, is focused on European middle-market buyout transactions sourced through Independent Sponsors. Since 2020 Eighteen48 Partners have deployed more than €200 million into this strategy, which aims to provide investors with diversified exposure to off-market sourced transactions. The first close was supported by significant re-up commitments from Eighteen48 clients as well as commitments from institutions, family offices and UHNWs, underscoring the strength of the firm’s platform, track record and experience as well as growing momentum in the Independent Sponsor space. Julien Sevaux, Founding Partner and CEO, commented: “We are increasingly excited by the opportunity in the growing independent sponsor segment of European private equity - a corner of the market we believe remains largely overlooked by investors yet offers compelling
Klarna Delivers Strong Start to 2026 With $1Bn Revenue and $68M Adj. Operating Profit14.5.2026 13:30:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, today reported first quarter 2026 results. GMV reached $33.7 billion (+33% YoY), revenue $1.0 billion (+44% YoY), transaction margin dollars $389 million (+44% YoY), and adjusted operating profit $68 million, up from $3 million a year ago. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514241288/en/ "Klarna addresses the entire consumer wallet: Pay Now for everyday spending and saving, Pay Later our charge card equivalent at 0% interest for mid-size ticket spending, and POS installments (Fair Financing) for big-ticket purchases. In Q1 we executed well across all the business, driving every line of our P&L and compounding growth across our global network. Growing network. Same three products. Deeper consumer engagement.” Sebastian Siemiatkowski, CEO & Co-Founder, Klarna Q1 2026 Highlights GMV: $33.7 billion (+33% YoY); U.S. +39%, ex-U.S. +31% Revenue: $1.0 bil
SBC Medical Group Holdings Announces First Quarter 2026 Financial Results14.5.2026 12:30:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization providing management support across a wide range of healthcare fields, today announced its financial results for the three months ended March 31, 2026. First Quarter 2026 Highlights Total revenues were $43 million, representing a 9% year-over-year decrease. Net income attributable to SBC Medical Group Holdings Incorporated was $11 million, representing a 47% year-over-year decrease. Net income margin was 26% for the first quarter of 2026, representing a year-over-year decrease of 19 percentage points. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.11 for the three months ended March 31, 2026, representing a 48% year-over-year decrease. EBITDA1, which is calculated by adding depreciation and amortization expense to income from operations was $18 million, representing a
Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 202614.5.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the RBC Capital Markets Global Healthcare Conference on May 19-20, 2026 and will participate in a fireside chat on May 19 at 10:00am ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of
FPT Strengthens Bavarian Presence with New Munich Office, Accelerating AI Transformation14.5.2026 11:13:00 CEST | Press release
Global technology corporation FPT officially cut the ribbon on its latest office in Germany. This milestone reinforces the company's long-term commitment to delivering AI-driven services to its growing customer base across Germany and the wider European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514689341/en/ The inauguration ceremony was attended by H.E. Mr Nguyen Dac Thanh, Ambassador of Vietnam to Germany, alongside representatives from the local government, FPT executives, and key partners. Situated in one of Europe’s most dynamic technological and manufacturing hubs, the Munich office strengthens FPT’s delivery capabilities and enables faster, more scalable engagement across the region. The move underscores the company’s strategic focus on investing in key innovation hubs to meet rising demand for AI transformation and accelerate time-to-value for clients. "Our expanded presence in Munich allows us to sta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom